Structure-guided drug design identifies a BRD4-selective small molecule that suppresses HIV

Qingli Niu, Zhiqing Liu, Edrous Alamer, Xiuzhen Fan, Haiying Chen, Janice Endsley, Benjamin B. Gelman, Bing Tian, Jerome H. Kim, Nelson L. Michael, Merlin L. Robb, Jintanat Ananworanich, Jia Zhou, Haitao Hu

Research output: Contribution to journalArticle

Abstract

HIV integrates its provirus into the host genome and establishes latent infection. Antiretroviral therapy (ART) can control HIV viremia, but cannot eradicate or cure the virus. Approaches targeting host epigenetic machinery to repress HIV, leading to an aviremic state free of ART, are needed. Bromodomain and extraterminal (BET) family protein BRD4 is an epigenetic reader involved in HIV transcriptional regulation. Using structure-guided drug design, we identified a small molecule (ZL0580) that induced epigenetic suppression of HIV via BRD4. We showed that ZL0580 induced HIV suppression in multiple in vitro and ex vivo cell models. Combination treatment of cells of aviremic HIV-infected individuals with ART and ZL0580 revealed that ZL0580 accelerated HIV suppression during ART and delayed viral rebound after ART cessation. Mechanistically different from the BET/BRD4 pan-inhibitor JQ1, which nonselectively binds to BD1 and BD2 domains of all BET proteins, ZL0580 selectively bound to BD1 domain of BRD4. We further demonstrate that ZL0580 induced HIV suppression by inhibiting Tat transactivation and transcription elongation as well as by inducing repressive chromatin structure at the HIV promoter. Our findings establish a proof of concept for modulation of BRD4 to epigenetically suppress HIV and provide a promising chemical scaffold for the development of probes and/or therapeutic agents for HIV epigenetic silencing.

Original languageEnglish (US)
Pages (from-to)3361-3373
Number of pages13
JournalJournal of Clinical Investigation
Volume129
Issue number8
DOIs
StatePublished - Aug 1 2019

Fingerprint

Drug Design
HIV
Epigenomics
Therapeutics
Proviruses
Viremia
Transcriptional Activation
Chromatin
Proteins
Genome

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Structure-guided drug design identifies a BRD4-selective small molecule that suppresses HIV. / Niu, Qingli; Liu, Zhiqing; Alamer, Edrous; Fan, Xiuzhen; Chen, Haiying; Endsley, Janice; Gelman, Benjamin B.; Tian, Bing; Kim, Jerome H.; Michael, Nelson L.; Robb, Merlin L.; Ananworanich, Jintanat; Zhou, Jia; Hu, Haitao.

In: Journal of Clinical Investigation, Vol. 129, No. 8, 01.08.2019, p. 3361-3373.

Research output: Contribution to journalArticle

Niu, Q, Liu, Z, Alamer, E, Fan, X, Chen, H, Endsley, J, Gelman, BB, Tian, B, Kim, JH, Michael, NL, Robb, ML, Ananworanich, J, Zhou, J & Hu, H 2019, 'Structure-guided drug design identifies a BRD4-selective small molecule that suppresses HIV', Journal of Clinical Investigation, vol. 129, no. 8, pp. 3361-3373. https://doi.org/10.1172/JCI120633
Niu, Qingli ; Liu, Zhiqing ; Alamer, Edrous ; Fan, Xiuzhen ; Chen, Haiying ; Endsley, Janice ; Gelman, Benjamin B. ; Tian, Bing ; Kim, Jerome H. ; Michael, Nelson L. ; Robb, Merlin L. ; Ananworanich, Jintanat ; Zhou, Jia ; Hu, Haitao. / Structure-guided drug design identifies a BRD4-selective small molecule that suppresses HIV. In: Journal of Clinical Investigation. 2019 ; Vol. 129, No. 8. pp. 3361-3373.
@article{473ef5f2c1ed4d7da3e52e87c813da1b,
title = "Structure-guided drug design identifies a BRD4-selective small molecule that suppresses HIV",
abstract = "HIV integrates its provirus into the host genome and establishes latent infection. Antiretroviral therapy (ART) can control HIV viremia, but cannot eradicate or cure the virus. Approaches targeting host epigenetic machinery to repress HIV, leading to an aviremic state free of ART, are needed. Bromodomain and extraterminal (BET) family protein BRD4 is an epigenetic reader involved in HIV transcriptional regulation. Using structure-guided drug design, we identified a small molecule (ZL0580) that induced epigenetic suppression of HIV via BRD4. We showed that ZL0580 induced HIV suppression in multiple in vitro and ex vivo cell models. Combination treatment of cells of aviremic HIV-infected individuals with ART and ZL0580 revealed that ZL0580 accelerated HIV suppression during ART and delayed viral rebound after ART cessation. Mechanistically different from the BET/BRD4 pan-inhibitor JQ1, which nonselectively binds to BD1 and BD2 domains of all BET proteins, ZL0580 selectively bound to BD1 domain of BRD4. We further demonstrate that ZL0580 induced HIV suppression by inhibiting Tat transactivation and transcription elongation as well as by inducing repressive chromatin structure at the HIV promoter. Our findings establish a proof of concept for modulation of BRD4 to epigenetically suppress HIV and provide a promising chemical scaffold for the development of probes and/or therapeutic agents for HIV epigenetic silencing.",
author = "Qingli Niu and Zhiqing Liu and Edrous Alamer and Xiuzhen Fan and Haiying Chen and Janice Endsley and Gelman, {Benjamin B.} and Bing Tian and Kim, {Jerome H.} and Michael, {Nelson L.} and Robb, {Merlin L.} and Jintanat Ananworanich and Jia Zhou and Haitao Hu",
year = "2019",
month = "8",
day = "1",
doi = "10.1172/JCI120633",
language = "English (US)",
volume = "129",
pages = "3361--3373",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "8",

}

TY - JOUR

T1 - Structure-guided drug design identifies a BRD4-selective small molecule that suppresses HIV

AU - Niu, Qingli

AU - Liu, Zhiqing

AU - Alamer, Edrous

AU - Fan, Xiuzhen

AU - Chen, Haiying

AU - Endsley, Janice

AU - Gelman, Benjamin B.

AU - Tian, Bing

AU - Kim, Jerome H.

AU - Michael, Nelson L.

AU - Robb, Merlin L.

AU - Ananworanich, Jintanat

AU - Zhou, Jia

AU - Hu, Haitao

PY - 2019/8/1

Y1 - 2019/8/1

N2 - HIV integrates its provirus into the host genome and establishes latent infection. Antiretroviral therapy (ART) can control HIV viremia, but cannot eradicate or cure the virus. Approaches targeting host epigenetic machinery to repress HIV, leading to an aviremic state free of ART, are needed. Bromodomain and extraterminal (BET) family protein BRD4 is an epigenetic reader involved in HIV transcriptional regulation. Using structure-guided drug design, we identified a small molecule (ZL0580) that induced epigenetic suppression of HIV via BRD4. We showed that ZL0580 induced HIV suppression in multiple in vitro and ex vivo cell models. Combination treatment of cells of aviremic HIV-infected individuals with ART and ZL0580 revealed that ZL0580 accelerated HIV suppression during ART and delayed viral rebound after ART cessation. Mechanistically different from the BET/BRD4 pan-inhibitor JQ1, which nonselectively binds to BD1 and BD2 domains of all BET proteins, ZL0580 selectively bound to BD1 domain of BRD4. We further demonstrate that ZL0580 induced HIV suppression by inhibiting Tat transactivation and transcription elongation as well as by inducing repressive chromatin structure at the HIV promoter. Our findings establish a proof of concept for modulation of BRD4 to epigenetically suppress HIV and provide a promising chemical scaffold for the development of probes and/or therapeutic agents for HIV epigenetic silencing.

AB - HIV integrates its provirus into the host genome and establishes latent infection. Antiretroviral therapy (ART) can control HIV viremia, but cannot eradicate or cure the virus. Approaches targeting host epigenetic machinery to repress HIV, leading to an aviremic state free of ART, are needed. Bromodomain and extraterminal (BET) family protein BRD4 is an epigenetic reader involved in HIV transcriptional regulation. Using structure-guided drug design, we identified a small molecule (ZL0580) that induced epigenetic suppression of HIV via BRD4. We showed that ZL0580 induced HIV suppression in multiple in vitro and ex vivo cell models. Combination treatment of cells of aviremic HIV-infected individuals with ART and ZL0580 revealed that ZL0580 accelerated HIV suppression during ART and delayed viral rebound after ART cessation. Mechanistically different from the BET/BRD4 pan-inhibitor JQ1, which nonselectively binds to BD1 and BD2 domains of all BET proteins, ZL0580 selectively bound to BD1 domain of BRD4. We further demonstrate that ZL0580 induced HIV suppression by inhibiting Tat transactivation and transcription elongation as well as by inducing repressive chromatin structure at the HIV promoter. Our findings establish a proof of concept for modulation of BRD4 to epigenetically suppress HIV and provide a promising chemical scaffold for the development of probes and/or therapeutic agents for HIV epigenetic silencing.

UR - http://www.scopus.com/inward/record.url?scp=85073703720&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073703720&partnerID=8YFLogxK

U2 - 10.1172/JCI120633

DO - 10.1172/JCI120633

M3 - Article

C2 - 31329163

AN - SCOPUS:85073703720

VL - 129

SP - 3361

EP - 3373

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 8

ER -